The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 54 cents per share of common stock.
McKesson Corporation Declares Quarterly Dividend – April 27, 2023 Read More »
Takeda today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) resubmission for the investigational subcutaneous (SC) administration of Entyvio® (vedolizumab) for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) after induction therapy with Entyvio intravenous.
Se ha confirmado experimentalmente una peculiar conjetura sobre la información cuántica. Algunas cosas están relacionadas, otras no. Supongamos que seleccionamos al azar entre la multitud a una persona que es significativamente más alta que la media. En ese caso, …
¿De qué depende que las partículas de un sistema cuántico compartan información? Read More »
Cryoport, Inc. today announced that the Company will report financial results for the first quarter ended March 31, 2023.
Cryoport to Report First Quarter 2023 Financial Results on May 4, 2023 Read More »
Nektar Therapeutics (Nasdaq: NKTR) today announced that it will be regaining the full rights to REZPEG from Eli Lilly and Company.
While MBAs can reflect positively on job applicants, work experience can often be more valuable, depending on the area.
Merck and AstraZeneca are seeking broad approval for Lynparza in mCRPC regardless of BRCA status.
FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm Read More »
La Voyager 2 y su “hermana gemela” Voyager 1 son las únicas naves espaciales de la Tierra que están en funcionamiento en el espacio interestelar. Ambas están ayudando a hacer descubrimientos científicos sobre la forma de la heliosfera (la burbuja protectora de …
Los planes futuros para la sonda interestelar Voyager 2 Read More »
Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.
Eli Lilly and Company announced that tirzepatide achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.
